Why Semaglutide is an inflection point for India’s generics sector?
The expiry of Novo Nordisk's primary patent for Semaglutide in India this March has opened a multi-billion-dollar opportunity for the country's pharmaceutical industry, which supplies 20% of the world's generics. Over 40 Indian firms, including Sun Pharma and Dr. Reddy's, plan to launch their own generic versions to cater to the significant domestic market of over 10 crore diabetes patients. This development reflects a broader trend where patent expiries historically boost growth in India's generics sector, potentially expanding into markets like Brazil and China.